Vapotherm Inc is a medical technology company based in the United States... Show more
The 50-day moving average for VAPO moved above the 200-day moving average on July 09, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.341) is normal, around the industry mean (24.348). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.255) is also within normal values, averaging (42.660).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VAPO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VAPO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
a developer of respiratory devices
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, VAPO has been loosely correlated with LUNG. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if VAPO jumps, then LUNG could also see price increases.
Ticker / NAME | Correlation To VAPO | 1D Price Change % | ||
---|---|---|---|---|
VAPO | 100% | N/A | ||
LUNG - VAPO | 43% Loosely correlated | -2.93% | ||
SRTS - VAPO | 33% Loosely correlated | -0.65% | ||
NSYS - VAPO | 30% Poorly correlated | +0.53% | ||
EW - VAPO | 27% Poorly correlated | +2.09% | ||
TNDM - VAPO | 26% Poorly correlated | +2.02% | ||
More |
Ticker / NAME | Correlation To VAPO | 1D Price Change % |
---|---|---|
VAPO | 100% | N/A |
medical research theme (120 stocks) | 5% Poorly correlated | -1.92% |
medical service theme (146 stocks) | 5% Poorly correlated | -1.92% |
Medical Specialties theme (422 stocks) | -3% Poorly correlated | -1.60% |
Medical Specialties theme (392 stocks) | -4% Poorly correlated | -1.59% |